RE:RE:TSX-VAgreed. The uplist is an added bonus. License will be the major catalyst going forward. The selection of inventory avail across multi level platforms will be unparalleled.
Not pumping just stating the facts. With recent nr when deal settles they just added 1200 plus patients to their growing base.
N already has the tech to rapidly increase patient count. Irrelevant what market sentiment is today. If you're long on the mj sector and dont let your judgement get clouded by a few misinformed here N won't disappoint.